title: Assessment of dose-intensive therapy in suboptimally debulked ovarian cancer: a Gynecologic Oncology Group study.
abstract: OBJECTIVE
  We report a prospective randomized trial in women with advanced ovarian cancer to evaluate the importance of chemotherapy dose-intensity on survival, progression-free survival (PFS), and response.
  
  
  METHODS
  A total of 485 patients with epithelial ovarian cancer and residual masses more than 1 cm following surgery (stage III presentation) or any stage IV presentation were randomly assigned to receive either standard therapy (cyclophosphamide 500 mg/m2 and cisplatin 50 mg/m2 intravenously every 3 weeks for eight courses) or intense therapy (cyclophosphamide 1,000 mg/m2 and cisplatin 100 mg/m2 intravenously every 3 weeks for four courses). Dose modification was rigidly controlled to maintain intensity. Clinical and pathologic responses were assessed, when appropriate, as well as PFS interval and survival.
  
  
  RESULTS
  A total of 458 patients met all eligibility criteria and were assessed for survival and PFS. The dose-intensive group received the same total dose of cyclophosphamide and cisplatin, but 1.97 times greater dose-intensity than the standard group. Clinical and pathologic response rates; response duration, and survival were similar in both groups of patients. Hematologic, gastrointestinal, febrile episodes, septic events, and renal toxicities were significantly more common and severe in the dose-intensive group.
  
  
  CONCLUSIONS
  A doubling of the dose-intensity in the treatment of bulky ovarian epithelial cancers led to no discernible improvement in patient outcome and was associated with more severe toxicity. This study provides no evidence to support the hypothesis that modest increases in dose-intensity without increasing total dose are associated with significant improvement in overall survival or PFS.
authors.affiliation: Department of Medicine, Emory University, Atlanta, GA, USA.
authors.forename: W P
authors.initials: WP
authors.lastname: McGuire
authors.forename: W J
authors.initials: WJ
authors.lastname: Hoskins
authors.forename: M F
authors.initials: MF
authors.lastname: Brady
authors.forename: H D
authors.initials: HD
authors.lastname: Homesley
authors.forename: W T
authors.initials: WT
authors.lastname: Creasman
authors.forename: M L
authors.initials: ML
authors.lastname: Berman
authors.forename: H
authors.initials: H
authors.lastname: Ball
authors.forename: J S
authors.initials: JS
authors.lastname: Berek
authors.forename: J
authors.initials: J
authors.lastname: Woodward
mesh_terms: D000328:Adult; D000367:Age Factors; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D002423:Cause of Death; D002945:Cisplatin / Q000008:administration & dosage; D003520:Cyclophosphamide / Q000008:administration & dosage; D018450:Disease Progression; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology / Q000601:surgery; D011379:Prognosis; D011446:Prospective Studies; D012086:Reoperation
chemical_list: D003520:Cyclophosphamide; D002945:Cisplatin